Adding Statins to ADT May Delay PCa Progression

Adding Statins to ADT May Delay PCa Progression

ORLANDO, Fla.—Taking a statin during treatment with androgen deprivation therapy (ADT) might lengthen the time before a prostate cancer (PCa) becomes resistant, according to new...

Adding ADT to Radiotherapy Improves Prostate Cancer Outcomes

Adding ADT to Radiotherapy Improves Prostate Cancer Outcomes

Adding 6 months of androgen deprivation therapy (ADT) to radiotherapy for localized prostate cancer (PCa) decreases the risk of biochemical progression, according to study data...

Adding Statins to ADT May Delay PCa Progression

Adding Statins to ADT May Delay PCa Progression

ORLANDO, Fla.—Taking a statin during treatment with androgen deprivation therapy (ADT) might lengthen the time before a prostate cancer (PCa) becomes resistant, according to new...

Statins Plus ADT After Prostate Cancer Radiotherapy Ups Survival

Statins Plus ADT After Prostate Cancer Radiotherapy Ups Survival

ORLANDO, Fla.—Adding statins to androgen-deprivation therapy (ADT) may improve survival among men who experience biochemical recurrence of prostate cancer (PCa) following...

Short-Term ADT+Radiotherapy Does Not Help Intermediate PCa Survival

Short-Term ADT+Radiotherapy Does Not Help Intermediate PCa Survival

ORLANDO—Adding short-term androgen deprivation therapy (STADT) to radiotherapy does not improve overall survival (OS) among men with intermediate-risk prostate cancer (IRPC),...

Low Testosterone After ADT Linked with Improved Survival

Low Testosterone After ADT Linked with Improved Survival

Low serum testosterone levels within the first year of androgen-deprivation therapy (ADT) in men with castration-resistant prostate cancer (PCa) undergoing continuous androgen...

Primary ADT Not Beneficial in Most Cases of Early Prostate Cancer

Primary ADT Not Beneficial in Most Cases of Early Prostate Cancer

Recent study results indicate that the majority of men with clinically localized prostate cancer (PCa) derive no survival benefit from the administration of primary androgen...

Androgen Deprivation Therapy Increases Diabetes Risk

Androgen Deprivation Therapy Increases Diabetes Risk

(HealthDay News) -- Primary androgen deprivation therapy increases diabetes risk, particularly in men under 70 years of age, according to research published in The Journal of...

ADT Plus Docetaxel Chemo May Increase Survival in Metastatic Prostate Cancer

ADT Plus Docetaxel Chemo May Increase Survival in Metastatic Prostate Cancer

(HealthDay News) -- Chemotherapy at the start of androgen-deprivation therapy (ADT) can extend the lives of men with metastatic, hormone-sensitive prostate cancer, according to...

Preop ADT Could Potentially Eradicate High-Risk Prostate Tumors

Preop ADT Could Potentially Eradicate High-Risk Prostate Tumors

Androgen deprivation therapy (ADT) prior to radical prostatectomy (RP) for high-risk prostate cancer has the potential to completely eliminate the tumors and improve outcomes,...

Early ADT for Recurrent Prostate Cancer May Hike Death Risk

Early ADT for Recurrent Prostate Cancer May Hike Death Risk

NEW ORLEANS—Early androgen deprivation therapy (ADT) may increase the risk of death among men who receive it after experiencing biochemical recurrence (BCR) of prostate cancer...

Androgen Deprivation for Localized Prostate Cancer Ups Cardiac Risks

Androgen Deprivation for Localized Prostate Cancer Ups Cardiac Risks

Androgen deprivation therapy (ADT) with gonadotropin-releasing hormone (GnRH) agonists is associated with an increased risk of cardiac events in elderly men with localized...